Adjuvants are considered a necessary component for HBV therapeutic vaccines but few are licensed in clinical practice due to concerns about safety or efficiency. In our recent study, we established that a combination protocol of 3-day pretreatments with GM-CSF before a vaccination (3 £ GM-CSFCVACCINE) into the same injection site could break immune tolerance and cause over 90% reduction of HBsAg level in the HBsAg transgenic mouse model. Herein, we further investigated the therapeutic potential of the combination in AAV8-1.3HBV-infected mice. After 4 vaccinations, both serum HBeAg and HBsAg were cleared and there was a 95% reduction of HBV-positive hepatocytes, in addition to the presence of large number of infiltrating CD8
Introduction
HBV (Hepatitis B Virus) infection is a global threat and a major cause of chronic hepatitis, and hepatocellular carcinoma. 1 Current therapies based on interferon-a (IFN-a) and/or nucleotide/nucleoside analogs fail to clear viral infection in the majority of chronic hepatitis B (CHB) patients. 2, 3 Immunological tolerance underlies viral persistence during chronic HBV infection. 4 Consequently, immunotherapeutic vaccine effectiveness is linked to ability to break the tolerance. Several candidate HBV therapeutic vaccines are based on DNA, peptide, dendritic cells, and recombinant proteins. Notably, appropriate adjuvants are necessary for these vaccines. In animal models, alum, 5 saponin, 6 and CpG 7 are used as effective adjuvants to enhance the efficiency of the HBV vaccine. However, safety concerns limit the extension to clinical practice. By contrast, several drugs and cytokines for treating human diseases, such as levamisole 8 and GM-CSF 9 are also proven adjuvants that can evoke effective immune responses to HBV vaccines.
GM-CSF is a potent haematopoietic growth factor that has been used in clinical practice for more than 20 y. It can stimulate and enhance the production and activation of myeloid dendritic cells (DC). 10 Since GM-CSF promotes the function of antigen presenting cells (APCs), it has been used as an immunostimulatory adjuvant for experimental anti-tumor and anti-virus vaccines. 11, 12 However, several contradictory studies indicated that the inappropriate use of GM-CSF could induce suppressive immune responses. 13 The underlying mechanisms remain to be defined, but the induction of immature DCs might be involved. 14, 15 The capture of HBV antigens by DC before they had sufficient time to mature could have undesirable immunosuppressive effects. 16 With this consideration, we hypothesized that pre-treatment with GM-CSF for more than one day could promote DCs to become fully mature such that subsequent HBV vaccination could evoke a potent HBV-specific immune response in animals.
In a recent work, we designed a novel protocol by using a combination of GM-CSF and HBsAg vaccine and evaluated its effectiveness in an HBsAg-expressing transgenic mouse model (official model designation, Tg [Alb-1 HBV] Bri 44). One course constitutes daily GM-CSF for 3 times, followed by HBsAg vaccination (3 £ GM-CSFCVACCINE). The mice were given 3 courses at 2-week intervals. 17 The HBsAg transgenic mice with HBV sequences encoding for viral proteins pre-S, S, and X did not respond to a conventional HBsAg vaccine. In contrast, we observed that the 3 £ GM-CSFCVAC-CINE treatment achieved 90% reduction of HBsAg level in the model via the activation of HBsAg specific CD8 C T cells. 18 Currently, the mouse is the most widely used experimental animal because of its short generation time and the fact that the mouse genome is easy to manipulate. 19 Various mouse models for persistent HBV infection have been generated in the past years, and these include HBsAg transgenic mice, 17 human liver chimeric mice for HBV infection, 20 and HBV genome delivery through hydrodynamic injection or through viral vector. 21, 22 However, each model has its limitations. For example, 2 major limitations of HBV transgenic mice are that HBV replicates from an integrated transgene that cannot be cleared and mouse hepatocytes do not establish covalently closed circular DNA (cccDNA). 23 Thus, the goals of therapeutic vaccination, namely, HBV clearance and elimination of cccDNA, cannot be achieved in this model. Human hepatocyte chimeric mice with livers efficiently replaced with human hepatocytes become susceptible for HBV infection and allow the formation of HBV cccDNA, but these chimeric mice are difficult to generate. 24 Hydrodynamic injection (HDI) of the HBV genome in mice can cause significant hepatocyte damage. 25 Furthermore, HBV replication and antigen expression after HDI is transient and HBV-specific immune responses are induced at 2 weeks after injection. 21 Recently, a recombinant adeno-associated virus (AAV) carrying 1.3 copies of the HBV genome (AAV8-1.3HBV) was used to establish chronic HBV infection. 22, 26 In AAV8-1.3HBV-transduced mice, the HBV genome was transduced into the hepatocytes and thus mimicked the natural HBV transcription template. Serum HBV DNA, HBeAg and HBsAg persisted for more than 10 months and no significant liver inflammation was observed; these observations were similar to those seen in chronic hepatitis B (CHB) patients in the immunotolerant stage. 27 Therefore, these AAV8-1.3HBV-infected mice have presented numerous interesting models for chronic HBV infection. 26 In this study, we further explore the immunopotential of 3 £ GM-CSF CVACCINE and its underlying mechanism in this mouse model infected with AAV8-1.3HBV.
Results
Strategy for the 3 £ GM-CSFCVACCINE immunization in the AAV8-1.3HBV mouse model
The schema of the proposed strategy for the 3 £ GM-CSFCVACCINE immunization as applied in the AAV8-1.3HBV mouse model is illustrated in Fig. 1A . The AAV8-1.3HBV infected mice were treated subcutaneously with 10 mg of GM-CSF once per day for 3 d and then subcutaneously injected with 1 mg of VACCINE at the same site. Treatment of all mice started on day 0, and 3 booster treatments were given, starting on days 14, 28, and 49. Mice treated with phosphate-buffered saline (PBS), GM-CSF, or VACCINE alone and GM-CSF/VACCINE coadministration were used as controls. Blood samples and local draining lymph nodes were obtained from each mouse at 24, 48, and 72 h post-vaccination. CD11 is commonly used as a mouse myeloid cells and DC marker. 28, 29 
CD11b
C Ly6C hi CCR2 C monocytes and CD11b The 3 £ GM-CSFCVACCINE promotes the activation of CD11b C CD11c C DC By design, the primary function of adjuvants is to activate antigen presenting cells (APCs), particularly DC, which are crucial to process and effectively present viral antigen and in turn to mount antigen-specific immune responses against invading pathogens. 30 To understand which APC subpopulation was activated by the 3 £ GM-CSFCVACCINE regimen, we isolated APCs from peripheral blood and local lymph nodes of mice at 1 to 3 d after the second immunization of 3 £ GM-CSFCVACCINE (Fig. 1A) . Mice that received the 3 £ GM-CSFCVACCINE exhibited an approximately five-and threefold higher frequency of CD11b C CD11c C DC in the blood and local lymph nodes, respectively, compared with the control mice (Fig. 1B and 1C) . However, this treatment did not alter the numbers of CD11b ¡ PDCA-1 C plasmacytoid DC and CD11b C F4/80 C macrophages ( Fig. S1A and S1B ). To evaluate whether the 3 £ GM-CSFCVACCINE promoted the activation of this newly increased DC population, we examined the expression levels of CD80, MHC-I and MHC-II ( Fig. 1D to 1F ) in the
significantly enhanced the expression levels of these functional molecules compared with the controls. To further assess whether the 3 £ GM-CSFCVACCINE induced a cytokine milieu environment containing cytokines in combinations that could subsequently influence the outcome of immune response, we examined several key inflammatory cytokines and chemokines in the serum using ELISA. The results showed that the 3 £ GM-CSFCVACCINE treatments significantly enhanced the concentration of IL-12 ( Fig. 1G ) and of the monocyte chemo-attractant protein-1 (MCP-1), a chemokine that attracts monocytes and traffics them into an inflammatory site (Fig. 1H) . These results suggested that 3 £ GM-CSFCVACCINE could markedly enhance the availability of immunogenic CD11b
C CD11c C DC in vivo.
The 3 £ GM-CSFCVACCINE drives the production of CD11b C Ly6C hi monocytes
Monocytes can develop into DC in the presence of GM-CSF. 31 To evaluate whether the 3 pretreatments of GM-CSF (3 £ 
GM-CSF) could influence monocyte differentiation into
MoDC, we sorted blood CD11b C Ly6G ¡ monocytes from wild type C57B/6 mice and treated them with GM-CSF once daily for 3 d (3 £ GM-CSF) in vitro. Untreated cells and those treated once only with LPS or GM-CSF were used as controls. As shown in Fig. 2A, 3 £ GM-CSF enriched the monocytes and promoted a higher rate of conversion to CD11c
C DC compared with the treatment with GM-CSF once. This was accompanied by higher levels of functional molecules CD80 (Fig. 2B) , MHC-I (Fig. 2C) , and MHC-II (Fig. 2D) , showing changes similar to those seen in vivo. To further characterize the function of these monocyte-derived DC (MoDC), we used the 3 £ GM-CSF-induced MoDC for incubation with 10 mg/mL of HBsAg and purified splenic CD8 C T cells (2 £ 10 5 cells/well) from AAV8-1.3HBV infected mice and further co-cultured them at a MoDC:T ratio of 1:10. As shown in Fig. 2E and 2F, the 3 £ GM-CSF-induced MoDC promoted a significantly higher level of CD8 C T-cell proliferation than those induced by the single GM-CSF treatment.
MoDC are continuously generated from the blood Ly6C hi monocytes in vivo; 32 therefore, we examined which subtype of monocyte assisted this process in HBV-infected mice. The monocytes in the peripheral blood were determined at 24, 48, and 72 h after the last immunization, wherein mice were immunized with 3 £ GM-CSFCVACCINE twice at 2-week intervals. By 24 h, mice that received 3 £ GM-CSFCVACCINE presented an approximately 3.5-fold higher frequency of CD11b C Ly6C hi monocytes in the blood than controls did ( Fig. 2G and 2H) . Moreover, the frequency of CD11b C Ly6C lo monocytes did not change (Figs. S2A and S2B ). CCR2 on Ly6C hi monocytes reportedly plays a guiding role and enables cells to traffic to inflammatory sites. 33 Correspondingly, an elevation in the serum level of MCP-1 (a CCR2 chemotactic ligand) was observed in the 3 £ GM-CSFCVACCINE-treated group (Fig. 1H) . Echoing this finding, the 3 £ GM-CSFCVAC-CINE significantly enhanced the expression of CCR2 on CD11b
C

Ly6C
hi monocytes compared with other controls (Fig. S2C) , indicating that MCP-1/CCR2 pairs may be essential for the Ly6C hi monocytes trafficking to the infected sites in immunized mice.
The 3 £ GM-CSFCVACCINE induces robust HBV specific CD8
C T-cell response in vivo
A robust HBV-specific CD8 C T cell response plays a crucial role in eliminating virally infected hepatocytes. 34, 35 We assessed the antigen specific cellular responses to the protocol shown in Fig. 1A at 14 d after the last immunization. The 3 £ GM-CSFCVACCINE induced significantly increased HBsAg-specific IFN-g C CD8 C T cells in the periphery (Fig. 3A and 3B ). Through IHC, a similar trend was found for CD8
C T cell infiltrates in the liver (Fig. 3C) . A HBV-specific CTL response is essential to clear the intracellular virus, 36, 37 and was assessed as shown in Fig. 3D . As shown in Fig. 3E and 3F, HBsAg-specific killing was almost 50% in the 3 £ GM-CSFCVACCINE group, whereas the level of CTL response of mice that received control immunizations was less than 10%. Collectively, these results suggested that the 3 £ GM-CSFCVACCINE could facilitate a robust HBsAg-specific CD8 C T-cell response in the AAV8-1.3HBV mouse model.
The 3 £ GM-CSFCVACCINE enhances humoral response and induces HBV clearance in the mouse model
We next investigated the possible therapeutic effect of the 3 £ GM-CSFCVACCINE in the AAV8-1.3HBV mouse model. The mice were immunized with the 3 £ GM-CSFCVACCINE according to the designed immunization strategy (Fig. 1A) . Mice treated with PBS, GM-CSF or VACCINE alone and GM-CSF/VACCINE co-treated mice were used as controls. Fourteen days after the fourth vaccination, serum samples of immunized AAV8-1.8HBV mice were collected for HBeAg, HBsAg, HBV DNA and antiHBsAg antibody tests. Liver tissues were collected for HBV DNA, IHC and pathology tests. The results demonstrated that serum HBeAg (Fig. 4A) and HBsAg (Fig. 4B) were cleared in the 3 £ GM-CSFCVACCINE group, which was in marked contrast to the controls. Treatment with 3 £ GM-CSFCVACCINE promoted substantial production of anti-HBsAg antibody, whereas no HBsAg-specific antibodies were detectable in controls (Fig. 4C) . To analyze whether 3 £ GM-CSFCVACCINE influences IgG subclasses, we determined the levels of IgG1 and IgG2c at intervals during 24 weeks. After immunization with 3 £ GM-CSFCVAC-CINE the AAV8-1.3HBV infected mice mounted strong IgG2c responses by weeks 9 and 12 and there were strong IgG1 responses on weeks 16, 20, and 24 (Fig. 4D) . To evaluate the long-term therapy with the 3 £ GM-CSFCVAC-CINE for the HBV mouse model, we monitored the serum HBeAg and HBsAg levels for 24 weeks. No rebounds were found in either HBeAg or HBsAg in 3 £ GM-CSF CVACCINE group (Fig. 4E and 4F ). Notably, the serum level of ALT was about 2.5-fold higher in the 3 £ GM-CSFCVACCINE group than in controls. Consistent with these findings, we observed a large number of lymphocytes trafficking in the 3 £ GM-CSFCVACCINE-treated mice livers (Fig. 4I) . However, the elevation of ALT was transient and decreased to the baseline level after the termination of anti-HBV treatment (Fig. 4F) . Furthermore, serum and liver HBV DNA levels declined >2 log 10 IU/mL and >2 log 10 IU/ g, respectively, in the 3 £ GM-CSF CVACCINE group ( Fig. 4H and 4I) .
To further assess the therapeutic effects of this regimen, we analyzed the clearance of HBcAg-positive hepatocytes and lymphocyte infiltrations in the livers of immunized AAV8-1.3HBV mice. As shown in Fig. 4J and 4K, significant clearance of HBcAg-positive hepatocytes was observed after 3 £ GM-CSFCVACCINE immunizations compared with controls. Taken together, these results highlighted a broader relevance for the robust anti-HBV responses induced by 3 £ GM-CSFCVACCINE in the immune-tolerance model infected with AAV8-1.3HBV.
Depletion of Ly6C hi monocytes abolishes viral elimination of HBV model mice
Having demonstrated that the antigen specific CD8 C T cell response was induced by CCR2
C
Ly6C
hi monocytes, we determined whether the selective blockade of Ly6C hi monocytes would exert a detrimental effect on MoDC-mediated HBV clearance. We intraperitoneally injected INCB3344, a selective CCR2 antagonist, 38 into the HBV mouse model 1 h before the GM-CSF administration, and re-injected on days 2, 3, and 4. Mice treated with PBS or the DMSO vehicle were used as controls. Blood samples were collected, and peripheral blood mononuclear cells (PBMC) were analyzed 12 h after the fourth administration of INCB 3344. This pharmacological blockade of CCR2 prevented the generation of CD11b (Fig. 5A ) and CD11b C CD11c C DC (Fig. 5B) . To assess the importance of CCR2
C
Ly6C
hi monocytes, we examined whether the blockade of CCR2 T cells as well as the elevation of ALT level after 3 £ GM-CSFCVACCINE treatments (Fig. 5C and 5D ). Similar serum levels of viral load and HBsAg were found in PBSand INCB3344-treated mice (Fig. 5E and 5F ). As shown in Fig. 5G , the blockade of CCR2 abrogated HBcAg-positive hepatocyte elimination. In summary, the induction of CCR2 C Ly6C hi monocytes by 3 £ GM-CSFCVACCINE immunization appeared to be crucial for the increased presence of CD11b
C
CD11c
C DC and the subsequent induction of robust anti-HBV responses.
Discussion
Here we demonstrated that an enrichment of CD11b C Ly6C hi monocytes participated in the HBV-specific responses induced by multiple GM-CSF injections(once daily for 3 days) followed by a HBV vaccination at the same injected site, and resulted in viral clearance in the AAV8-1.3HBV-infected mice models. This strategy mainly promoted CD11b
DC that elicited HBV specific CD8
C cellular responses and CTL in a CCR2-dependent manner. CCR2 dependence was implicated by CCR2-blockade that reduced CD11b C Ly6C hi monocytes and abrogated HBV clearance. Thus, the 3 £ GM-CSFCVACCINE protocol could recruit more functionally relevant Ly6C hi monocytes and enhance DC functionally to boost HBsAg-specific CD8 C T cells and lead into the HBV clearance process in vivo.
Clinically, GM-CSF is the first cytokine documented to promote the differentiation of myeloid lineage cells into DC. 39 Given its effects, GM-CSF has been exploited as an adjuvant for cancer and virus vaccines in different animal models. 40, 41 Our recent work demonstrated that the 3 £ GM-CSFCVAC-CINE overcame the immune tolerance and elicited HBV-specific responses in the HBsAg transgenic mouse model. However, the underlying mechanism remained largely unknown. Murine monocytes comprise 2 populations, namely, the Ly6C ¡ circulating monocytes. Ly6C hi monocytes require the chemokine receptor CCR2 to migrate to inflammatory sites and up monocyte chemokine protein-1 (MCP-1) gradients. 42 The crucial role of Ly6C hi monocytes has been documented in preventing infectious diseases. 43, 44 Here we identified Ly6C hi CCR2 C monocytes as a crucial effector to 3 £ GM-CSFCVACCINE-induced HBV-specific response. Using a novel HBV mouse model, we demonstrated that 3 £ GM-CSFCVACCINE significantly promoted the production of Ly6C hi CCR2 C monocytes and CD11b C CD11c C DC. Moreover, we found that monocytes significantly developed into CD11c C DC when cultured in GM-CSF once for 3 d and then the 3 £ GM-CSF-derived CD11c C DC could markedly promote the proliferation of HBsAg specific CD8 C T cells. Interestingly, blockage of Ly6C hi monocytes could significantly reduce CD11b C CD11c
C DC-induced HBV clearance. This finding implied that Ly6C hi monocytes may assist the increase in 
CD11b
C CD11c C DC, and this enriches our understanding of the mode of action of the 3 £ GM-CSFCVACCINE.
HBV-specific CD8 C T cells have been associated with the elimination of chronic HBV infections. Several inhibitory receptors, such as CTLA-4, PD-1, and LAG-3, contribute to the defective action of the anti-HBV CD8 C T cells in hepatitis B. 45 However, efforts to treat CHB infections with anti-PD-1 antibody achieved limited success, 46 indicating that these approaches may not be sufficient for reviving the function of the exhausted CD8 C T cells. Notably, in CHB patients, higher PD-1 expression was found on the intrahepatic virus-specific CTLs 47 and these were less susceptible to functional recovery by PD-1 depletion 48 when compared with circulating virus-specific CTLs. Therefore, freshly activating the na€ ıve CD8 C T-cell repertoire becomes a more feasible approach. Interestingly, in this study, 3 £ GM-CSFCVACCINE markedly induced the IFN-g secretion of CD8
C T cells and augmented potent HBV-specific CTLs. The intrahepatic recruitment of HBV-specific CD8 C T-cell evidently leads to the killing of infected cells. 49 Correspondingly, we observed numerous recruited CD8
C T-cell infiltrated into the liver in the 3 £ GM-CSFCVACCINE group. Furthermore, we noted that IL-12, a key cytokine in the initiation of effector T-cell development, was higher in the 3 £ GM-CSFCVACCINE group than in other groups. These results demonstrated that the HBV clearance of AAV8-1.3HBV-infected mice could be attributed to the de novo HBV-specific CD8
C T cells arising after the 3 £ GM-CSFCVACCINE treatments.
We believe that the current protocol might be more readily translatable to potential success in a clinical trial. The both commercial available GM-CSF and the alum-absorbed CHOderived recombinant HBsAg vaccine have been approved to use with excellent safety profiles for more than 20 y. A pioneer clinical trial has demonstrated that the daily administration of GM-CSF to CHB patients significantly reduces HBV DNA levels in a safe and tolerable manner. However, the HBsAg seroconversion has not being observed. 50 Furthermore, HBsAg vaccine monotherapy for the CHB patients renders treatment has been demonstrated non-effective in a clinical study. 51 In this study, we observed that the 3 £ GM-CSFCVACCINE regimen could promote HBsAg-specific CD8 C T cellular immune responses, HBsAb seroconversion and lead to the HBV clearance. Considering the safety and efficiency of this regimen, we expect that it may be readily acceptable in clinical practice. A recent study published by Bian and colleagues showed that preS1-containing vaccine could overcome immune tolerance more effectively than HBsAg vaccine did in HBV carrier mice. 26 Although there are not middle and/or large S protein vaccines licensed today, we would expect that the strategy of 3 £ GM-CSFCpreS vaccine could be very interest to test in human clinical trials if this vaccine becoming available.
This study has several limitations. First, how the hepatic immune populations respond to the 3 £ GM-CSFCVACCINE regimen was not fully defined. Second, gene expression patterns associated with monocyte development into DC in response to the 3 £ GM-CSFCVACCINE treatment were not defined. However, with the current pace of ongoing research, answers to these questions are expected soon.
In conclusion, the data presented here indicates that this GM-CSF-based HBV therapeutic vaccine promotes HBVspecific responses by enhancing Ly6C hi monocyte-derived CD11b C CD11c C DC in a CCR2-dependent manner in a HBV carrier mouse model. Accordingly, we suggest that the 3 £ GM-CSFCVACCINE regimen presents a promising therapeutic strategy for CHB treatment.
Methods and materials
Experimental animals
Six-to eight-week-old C57BL/6 male mice were bought from Huafukang Laboratory Animal Co. Ltd (Beijing, China). All mice received 1 £ 10 10 TCID50 of AAV8-1.3HBV (genotype D, ayw, FivePlus, Beijing, China) virus through tail vein injection and were housed in environmentally-controlled conditions. All procedures were performed with the institutional animal use and care committee approval.
Vaccination
Alum-absorbed Chinese hamster ovary cell-derived recombinant HBsAg (VACCINE, thereafter) and recombinant human GM-CSF were kindly gifted by the Jingtan Biotech Corp. of China North Pharmaceutical Group (Shijiazhang, China). The AAV8-1.3HBV infected mice were treated subcutaneously with 10 mg of GM-CSF once per day for 3 days, then subcutaneously injected with 1 mg of VACCINE at the same site. All mice started treatment on day 0 and three booster 3-day courses were started on days 14, 28, 49. Mice treated with PBS, GM-CSF or VACCINE alone and GM-CSF/VACCINE were co-treated and used as controls.
Cultivating monocyte-derived DC
Blood CD11b
C
Ly6G
¡ monocytes were isolated from male wild-type C57BL/6 mice (n D 50) by Easysep TM mouse monocyte isolation kit (STEMCELL, Canada). These cells were cultured in media supplied with recombinant mouse GM-CSF (50 ng/mL, PeproTech) once per day in a humidified incubators with 5% CO 2 . Monocytes were plated at 2 £ 10 5 /mL in 24-well cell culture plates. After 72 hours, the cells were collected and analyzed by FACS.
In vitro MoDC and T cell co-culture
Conventional splenic CD8
C T cells were purified from AAV8-1.3HBV infected mice by a MajoSort kit (Biolegend) and labeled with carboxyfluorescein succinimidyl ester (CFSE). 1 £ GM-CSF-derived or 3 £ GM-CSF-derived MoDC were incubated with10 mg/mL of HBsAg (Guikang, Shanghai, China) for 24 hours before mixed with the purified CD8 C T cells (2 £ 10 5 cells/well) at a T:MoDC ratio of 10:1. After 3-day co-culture, cells were analyzed by FACS.
In vivo cytotoxic lysis assay
OVA-specific CTL epitope OVA 257-264 (SIINFWKL) and HBsAg-specific CTL epitope S 208-215 (ILSPFLPL; H-2 b -restricted) were synthesized (Sangon, Shanghai, China). In vivo cytotoxic lysis assay was conducted as described previously. 18 Briefly, splenocytes from na€ ıve C57BL/6 donor mice were labeled with 15 mM of CFSE and pulsed with 1 mg/mL of S 208-215 (defined as CFSE high target cells). An equal fraction of splenocytes were labeled with 1 mM of CFSE and pulsed with 1 mg/mL of OVA [257] [258] [259] [260] [261] [262] [263] [264] Biochemical, serological and HBV DNA analysis Serum alanine aminotransferase activity (ALT) was determined by ALT kits (BioSino, Beijing, China). Serum HBsAg, HBsAb and HBeAg were measured by ELISA kits (Kehua, Shanghai, China). Serum IL-12 and MCP-1 were analyzed by ELISA kits (eBioscience, USA). Liver and serum HBV DNA was analyzed by real-time quantitative PCR kit (Sansure, Hunan, China).
Histology and immunohistochemistry (IHC) analysis
On day 14 after the fourth immunization, dissected liver samples were collected and fixed in 4% paraformaldehyde for 3 d before being embedded in paraffin wax, and cut into 5 to 10 mm thick slices. The liver sections were stained with hematoxylin-eosin for histology analysis and incubated with polyclonal rabbit antibody for IHC analysis.
Flow cytometry detection
Fluorescent labeled antibodies used for flow cytometric analysis were: CD8 (53-6.7), F4/80 (BM8), CD80 (16-10A1), MHC-I (AF6.88.5.5.3), PDCA-1 (eBio927), MHC-II (M5/114.15.2) from eBioscience; and CD11b (M1/70), Ly6C (HK1.4), CCR2 (SA203G11), IFN-g (XMG1.2) from Biolegend; and CD11c (HL3) from BD. In cytokine detection, PMA (100 ng/mL) and ionomycin (1 mg/mL) were used as positive control stimulants. An LSRFortessa (BD Biosciences) was used for flow cytometry analyses.
Statistical analysis
Statistical analysis was performed using Student's t-test and P values less than 0.05 were deemed significant. 
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